Long-Term Open-Trial of Mizoribine with Prednisolone in 24 Patients with Multiple Sclerosis. Safety, Clinical and Magnetic Resonance Imaging Outcome.

DOI Web Site Web Site PubMed 被引用文献3件 参考文献20件

この論文をさがす

抄録

Object Mizoribine (MZR), imidazole nucleotide, inhibits purine synthesis and helper T cell functions. It is used as an immunosuppressant in chronic rheumatic arthritis in Japan. Twenty-four patients with relapsing-remitting and chronic progressive multiple sclerosis (MS) were studied for the long-term effects of MZR over 8 years. Methods Average daily MZR doses of 200 mg along with prednisolone (PSL) were administered in the patients studied. Ten of 24 patients were treated for more than 5 years. Results The mean relapse rate per year at entry (1.50±0.24, mean±SE, n=22) decreased [0.46±0.24 (n=19)] after two years. In 70% of the patients, the disability did not worsen. Eleven of 18 patients showed a mild decrease of the total lesion size in magnetic resonance imaging (MRI). Conclusion MZR was well tolerated and could be used for long-term in MS as an adjunctive immunosuppressant to PSL, and the PSL doses could be decreased. A further randomized controlled trial with PSL is necessary.<br>(Internal Medicine 38: 636-642, 1999)

収録刊行物

  • Internal Medicine

    Internal Medicine 38 (8), 636-642, 1999

    一般社団法人 日本内科学会

被引用文献 (3)*注記

もっと見る

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ